CBD-loaded NPs increases glucose uptake and attenuates palmitate-induced lipid accumulation in human HepG2 hepatocytes
-
Mazen M El-Hammadi [1] ; Javier Vázquez Bourgon [3] [4] ; Esther Berrocoso Dominguez [4] [2] [2] ; Benedicto Crespo Facorro [3] [4] ; Irene Suárez Pereira [4] [2] [6] ; Lucía Martín Banderas [1]
-
[1] Universidad de Sevilla
Universidad de Sevilla
Sevilla, España
-
[2] Universidad de Cádiz
Universidad de Cádiz
Cádiz, España
-
[3] Department of Psychiatry, School of Medicine, University Hospital Marqués de Valdecilla - IDIVAL, Santander, Spain.
-
[4] Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
-
[5] Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain
-
[6] Neuropsychopharmacology & Psychobiology Research Group, Department of Neuroscience, University ofCadiz, Cádiz, Spain
-
- Localización: RESCIFAR Revista Española de Ciencias Farmacéuticas, ISSN-e 2660-6356, Vol. 2, Nº. 2, 2021 (Ejemplar dedicado a: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA), págs. 200-201
- Idioma: inglés
- Enlaces
-
Resumen
Cannabidiol (CBD) is a non-psychoactive cannabinoid that exhibits pain relief, anti-inflammatory, anti-oxidant, anti-tumor and neuroprotective properties. Furthermore, many studies have concluded that CBD exhibits several effects on both lipid and glucose metabolism through its action on various receptors and several metabolites. Accordingly, it has been found to decrease total cholesterol levels and to increase HDL levels, reduce intracellular lipid content and attenuate liver steatosis. Additionally, CBD has shown the ability to alleviate the symptoms of insulin resistance, minimize incidence of diabetes in mice and reduce the possibility of the metabolic syndrome among cannabis users. So, the objective of present work is to prepare CBD-loaded PLGA nanoparticles (NPs) and test their ability to increase glucose uptake and inhibit lipid accumulation in human HepG2 hepatocytes.
